UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Second- and third-generation drugs for immuno-oncology treatment—The more the better?

European journal of cancer (1990), 2017-03, Vol.74, p.55-72

2017

Volltextzugriff (PDF)

Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?

Oncology, 2018-01, Vol.95 (5), p.257-269

2018

Volltextzugriff (PDF)

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Therapeutic advances in medical oncology, 2021, Vol.13, p.1758835920980558-1758835920980558

2021

Volltextzugriff (PDF)

Rückbildung B-RAF-Inhibitor-assoziierter Keratoakanthome durch Acitretin - welche Auswirkungen haben Retinoide auf den RAF/MEK/ERK-Signalweg?

Journal der Deutschen Dermatologischen Gesellschaft, 2014-08, Vol.12 (8), p.721-723

2014

Volltextzugriff (PDF)

Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16074-e16074

2019

Volltextzugriff (PDF)

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review

Translational lung cancer research, 2021-06, Vol.10 (6), p.2667-2682

2021

Volltextzugriff (PDF)

Targeting Developmental Pathways: The Achilles Heel of Cancer?

Oncology, 2017-09, Vol.93 (4), p.213-223

2017

Volltextzugriff (PDF)

Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review

Expert review of hematology, 2023-04, Vol.16 (4), p.237-243

2023

Volltextzugriff (PDF)

Retrospective Analysis of Treatment Pathways in Patients With BRAF V600E -mutant Metastatic Colorectal Carcinoma – MORSE CRC

Anticancer research, 2022-10, Vol.42 (10), p.4773-4785

2022

Volltextzugriff (PDF)

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?

Translational lung cancer research, 2018-09, Vol.7 (S3), p.S275-S279

2018

Volltextzugriff (PDF)

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis

Advances in therapy, 2020-02, Vol.37 (2), p.730-744

2020

Volltextzugriff (PDF)

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Journal der Deutschen Dermatologischen Gesellschaft, 2014-08, Vol.12 (8), p.721-723

2014

Volltextzugriff (PDF)

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC

Anticancer research, 2022-10, Vol.42 (10), p.4773-4785

2022

Volltextzugriff (PDF)

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

Journal of cancer research and clinical oncology, 2023-07, Vol.149 (7), p.3739-3752

2023

Volltextzugriff (PDF)

Overall survival in non-small cell lung cancer—what is clinically meaningful?

Translational lung cancer research, 2016-02, Vol.5 (1), p.115-119

2016

Volltextzugriff (PDF)

Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?

Anticancer research, 2015-11, Vol.35 (11), p.5745-5757

2015

Volltextzugriff (PDF)

Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?

Journal der Deutschen Dermatologischen Gesellschaft, 2014-08, Vol.12 (8), p.721-723

2014

Volltextzugriff (PDF)

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?

Translational lung cancer research, 2022-04, Vol.11 (4), p.697-701

2022

Volltextzugriff (PDF)

Rückbildung B‐RAF‐Inhibitor‐assoziierter Keratoakanthome durch Acitretin – welche Auswirkungen haben Retinoide auf den RAF/MEK/ERK‐Signalweg?

Journal der Deutschen Dermatologischen Gesellschaft, 2014-08, Vol.12 (8), p.721-723

2014

Volltextzugriff (PDF)

Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?

Translational lung cancer research, 2018-04, Vol.7 (S2), p.S153-S157

2018

Volltextzugriff (PDF)

Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer—the Holy Grail in cancer treatment?

Translational lung cancer research, 2015-06, Vol.4 (3), p.223-227

2015

Volltextzugriff (PDF)

P-185: Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 myeloma patients: a retrospective real-world study

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S138-S139

2021

Volltextzugriff (PDF)

Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?

Translational lung cancer research, 2017-12, Vol.6 (S1), p.S88-S91

2017

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(50)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(20)
Oncology
(18)
Female
(9)
Middle Aged
(9)
Male
(8)
Aged
(7)
Respiratory System
(7)
Adult
(6)
Radiology, Nuclear Medicine & Medical Imaging
(6)
Cancer
(5)
Hematology
(5)
Magnetic Resonance Imaging - Methods
(5)
Medicine
(5)
Medicine & Public Health
(5)
Patients
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Biological And Medical Sciences
(4)
Image Processing, Computer-Assisted - Methods
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Second- and third-generation drugs for immuno-oncology treatment—The more the better?

Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Rückbildung B-RAF-Inhibitor-assoziierter Keratoakanthome durch Acitretin - welche Auswirkungen haben Retinoide auf den RAF/MEK/ERK-Signalweg?

Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs)

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review

Targeting Developmental Pathways: The Achilles Heel of Cancer?

Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review

Retrospective Analysis of Treatment Pathways in Patients With BRAF V600E -mutant Metastatic Colorectal Carcinoma – MORSE CRC

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

Overall survival in non-small cell lung cancer—what is clinically meaningful?

Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?

Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?

Rückbildung B‐RAF‐Inhibitor‐assoziierter Keratoakanthome durch Acitretin – welche Auswirkungen haben Retinoide auf den RAF/MEK/ERK‐Signalweg?

Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?

Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer—the Holy Grail in cancer treatment?

P-185: Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 myeloma patients: a retrospective real-world study

Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?

Suchergebnisse filtern